[go: up one dir, main page]

AU2003234089A1 - Treatment of neural injury and neurodegenerative disease with statins - Google Patents

Treatment of neural injury and neurodegenerative disease with statins

Info

Publication number
AU2003234089A1
AU2003234089A1 AU2003234089A AU2003234089A AU2003234089A1 AU 2003234089 A1 AU2003234089 A1 AU 2003234089A1 AU 2003234089 A AU2003234089 A AU 2003234089A AU 2003234089 A AU2003234089 A AU 2003234089A AU 2003234089 A1 AU2003234089 A1 AU 2003234089A1
Authority
AU
Australia
Prior art keywords
statins
treatment
neurodegenerative disease
neural injury
neural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003234089A
Inventor
Michael Chopp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry Ford Health System
Original Assignee
Henry Ford Health System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry Ford Health System filed Critical Henry Ford Health System
Publication of AU2003234089A1 publication Critical patent/AU2003234089A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003234089A 2002-04-12 2003-04-14 Treatment of neural injury and neurodegenerative disease with statins Abandoned AU2003234089A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37256502P 2002-04-12 2002-04-12
US60/372,565 2002-04-12
PCT/US2003/011478 WO2003086379A1 (en) 2002-04-12 2003-04-14 Treatment of neural injury and neurodegenerative disease with statins

Publications (1)

Publication Number Publication Date
AU2003234089A1 true AU2003234089A1 (en) 2003-10-27

Family

ID=29250877

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003234089A Abandoned AU2003234089A1 (en) 2002-04-12 2003-04-14 Treatment of neural injury and neurodegenerative disease with statins

Country Status (2)

Country Link
AU (1) AU2003234089A1 (en)
WO (1) WO2003086379A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004247023A1 (en) 2003-05-16 2004-12-23 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
US7183285B2 (en) 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7163945B2 (en) 2004-04-29 2007-01-16 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7199126B2 (en) 2004-04-29 2007-04-03 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20080103105A1 (en) * 2006-09-22 2008-05-01 Braincells, Inc. HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS
ES2344826B1 (en) * 2009-03-06 2011-06-06 Neuron Biopharma, S.A. NEUROPROTECTORS COMPOUNDS.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274603B1 (en) * 1997-09-24 2001-08-14 Mcgill University Methods for increasing ApoE levels for the treatment of neurodegenerative disease
US6472421B1 (en) * 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor

Also Published As

Publication number Publication date
WO2003086379A1 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
AU2003290548A1 (en) Prevention and treatment of synucleinopathic disease
AU2003243551A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
AU2002303295B2 (en) Diagnosis and treatment of neural disease and injury using microvoltammetry
AU2003246102A1 (en) Method of examining allergic disease and drug for treating the same
AU2003220096A1 (en) Methods for alzheimer's disease treatment and cognitive enhancement
AU2002338265A1 (en) Molecules for disease detection and treatment
EP1487446A4 (en) Bicyclic heterocycles for the treatment of diabetes and other diseases
AU2003904328A0 (en) Diagnosis and treatment of neurodegenerative disorders
AU2003209150A1 (en) Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases
IL162850A0 (en) Nitric oxide donors for treatment of disease and injury
AU2003238242A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
AU2003234089A1 (en) Treatment of neural injury and neurodegenerative disease with statins
AU2003244132A1 (en) Method of examining allergic disaese and drug for treating the same
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2003270487A1 (en) Use of statins in the prevention and treatment of radiation injury and other disorders associated with reduced endothelial thrombomodulin
AU2003245858A1 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU2003231279A1 (en) Prevention and treatment of type 2 diabetes
AU2003228339A1 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
AU2003205174A1 (en) Molecules for disease detection and treatment
AU2002364890A1 (en) Molecules for disease detection and treatment
AU2001262741A1 (en) Medicines for the prevention and treatment of neurodegenerative diseases
AUPS255202A0 (en) Agents and methods for the treatment of disorders associated with motor neuron degeneration
AUPS295802A0 (en) Metallothionein based neuronal therapeutic and therapeutic methods
AU2003302271A1 (en) Methods of treating and/or preventing autoimmune diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase